UK markets open in 5 hours 12 minutes
NIKKEI 225
27,945.34 +370.91 (+1.35%) HANG SENG
19,501.84 +51.61 (+0.27%) CRUDE OIL
72.05 +0.59 (+0.83%) GOLD FUTURES
1,805.50 +4.00 (+0.22%) DOW
33,781.48 +183.56 (+0.55%) BTC-GBP
14,055.53 +229.15 (+1.66%)
Swedish Orphan Biovitrum AB (publ) (SOBI.ST)
Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
At close: 05:29PM CET
| Previous close | 208.50 |
| Open | 208.60 |
| Bid | 211.10 x 0 |
| Ask | 211.40 x 0 |
| Day's range | 206.20 - 212.80 |
| 52-week range | 174.20 - 245.50 |
| Volume | |
| Avg. volume | 404,842 |
| Market cap | 64.245B |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | 21.27 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories
LAUSANNE, Switzerland, July 08, 2022--ADC Therapeutics SA (NYSE: ADCT) today announced it has entered into an exclusive license agreement with Swedish Orphan Biovitrum AB (Sobi®) for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications outside of the United States, greater China, Singapore and Japan. The Marketing Authorization Application (MAA) for ZYNLONTA was validated by the European Medicines Agency (EMA) at the end of October 2021, and orphan d
© 2022 Yahoo. All rights reserved.
